-
Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.
J Virol. 2000 Feb;74(4):1961-72
PMID: 10644369
-
The antigenic structure of the HIV gp120 envelope glycoprotein.
Nature. 1998 Jun 18;393(6686):705-11
PMID: 9641684
-
Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.
Biochemistry. 2001 Feb 13;40(6):1662-70
PMID: 11327825
-
A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
J Virol. 2002 Jan;76(2):644-55
PMID: 11752155
-
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
J Virol. 2002 Mar;76(6):2683-91
PMID: 11861835
-
Pathology of equine infectious anemia. Proposed classification of pathological types of disease.
Cornell Vet. 1970 Jul;60(3):393-449
PMID: 5464752
-
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.
Virology. 1987 Jan;156(1):171-6
PMID: 3643678
-
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.
Science. 1987 Sep 11;237(4820):1351-5
PMID: 3629244
-
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature. 1998 Jun 18;393(6686):648-59
PMID: 9641677
-
CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
J Virol. 1998 Jun;72(6):4694-703
PMID: 9573233
-
Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
J Virol. 1998 Sep;72(9):7099-107
PMID: 9696803
-
Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.
J Virol. 1999 Jun;73(6):5225-30
PMID: 10233993
-
Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.
J Virol. 1999 Jul;73(7):5707-13
PMID: 10364321
-
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
Cell. 1988 Apr 8;53(1):55-67
PMID: 2450679
-
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
J Virol. 1988 Jun;62(6):2107-14
PMID: 2452899
-
Envelope sequences of two new United States HIV-1 isolates.
Virology. 1988 Jun;164(2):531-6
PMID: 3369091
-
Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.
Cell. 1988 Jul 1;54(1):57-63
PMID: 2838179
-
Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.
N Engl J Med. 1989 Dec 14;321(24):1621-5
PMID: 2586564
-
Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.
AIDS Res Hum Retroviruses. 1990 Mar;6(3):341-56
PMID: 1971182
-
Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1.
AIDS Res Hum Retroviruses. 1990 Mar;6(3):371-80
PMID: 2187500
-
Human immunodeficiency virus neutralizing antibodies in sera from North Americans and Africans.
J Acquir Immune Defic Syndr. 1990;3(8):810-6
PMID: 2366149
-
Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
J Virol. 1990 Aug;64(8):3779-91
PMID: 2370681
-
Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
Science. 1990 Nov 23;250(4984):1139-42
PMID: 2251501
-
Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
J Virol. 1991 Mar;65(3):1133-40
PMID: 1995942
-
Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.
J Virol. 1991 Apr;65(4):2119-23
PMID: 2002555
-
The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site.
J Virol. 1991 May;65(5):2682-5
PMID: 2016774
-
Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.
J Virol. 1992 Jan;66(1):235-43
PMID: 1727487
-
Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
J Virol. 1992 Mar;66(3):1823-31
PMID: 1637373
-
HIV interactions with CD4: a continuum of conformations and consequences.
Immunol Today. 1992 Jun;13(6):201-6
PMID: 1627247
-
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120.
Virology. 1992 Dec;191(2):732-42
PMID: 1280382
-
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
J Virol. 1993 Jul;67(7):3978-88
PMID: 7685405
-
Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.
J Virol. 1993 Aug;67(8):4557-65
PMID: 8331723
-
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
Virology. 1994 Mar;199(2):431-8
PMID: 8122371
-
Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
J Virol. 1994 Sep;68(9):5854-62
PMID: 7520095
-
Preparation and characterization of human HIV type 1 neutralizing reference sera.
AIDS Res Hum Retroviruses. 1995 Jul;11(7):783-7
PMID: 7546904
-
Immune escape and tropism of HIV.
Trends Microbiol. 1995 Sep;3(9):356-61
PMID: 8520889
-
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
J Infect Dis. 1996 Jan;173(1):60-7
PMID: 8537683
-
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
Science. 1996 Mar 15;271(5255):1582-6
PMID: 8599114
-
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science. 1996 May 10;272(5263):872-7
PMID: 8629022
-
Identification of a major co-receptor for primary isolates of HIV-1.
Nature. 1996 Jun 20;381(6584):661-6
PMID: 8649511
-
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1.
Science. 1996 Jun 28;272(5270):1955-8
PMID: 8658171
-
Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection.
J Virol. 1996 Aug;70(8):5306-11
PMID: 8764041
-
Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.
J Virol. 1997 Apr;71(4):2779-85
PMID: 9060632
-
Core structure of gp41 from the HIV envelope glycoprotein.
Cell. 1997 Apr 18;89(2):263-73
PMID: 9108481
-
Atomic structure of the ectodomain from HIV-1 gp41.
Nature. 1997 May 22;387(6631):426-30
PMID: 9163431
-
Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
J Infect Dis. 1997 Aug;176(2):384-97
PMID: 9237703
-
A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
J Virol. 2000 May;74(9):4183-91
PMID: 10756031